These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 25638496)

  • 21. A Molecular Pharmacologist's Guide to G Protein-Coupled Receptor Crystallography.
    Piscitelli CL; Kean J; de Graaf C; Deupi X
    Mol Pharmacol; 2015 Sep; 88(3):536-51. PubMed ID: 26152196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.
    Kooistra AJ; Kuhne S; de Esch IJ; Leurs R; de Graaf C
    Br J Pharmacol; 2013 Sep; 170(1):101-26. PubMed ID: 23713847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GPCRs through the keyhole: the role of protein flexibility in ligand binding to β-adrenoceptors.
    Emtage AL; Mistry SN; Fischer PM; Kellam B; Laughton CA
    J Biomol Struct Dyn; 2017 Sep; 35(12):2604-2619. PubMed ID: 27532213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design.
    Ciancetta A; Jacobson KA
    Methods Mol Biol; 2018; 1705():45-72. PubMed ID: 29188558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights from structural biology into the druggability of G protein-coupled receptors.
    Mason JS; Bortolato A; Congreve M; Marshall FH
    Trends Pharmacol Sci; 2012 May; 33(5):249-60. PubMed ID: 22465153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structures of class B G protein-coupled receptors: prospects for drug discovery.
    Hausch F
    Angew Chem Int Ed Engl; 2013 Dec; 52(49):12783-5. PubMed ID: 24127232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based drug design for G protein-coupled receptors.
    Congreve M; Dias JM; Marshall FH
    Prog Med Chem; 2014; 53():1-63. PubMed ID: 24418607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. G protein-coupled receptors--recent advances.
    Latek D; Modzelewska A; Trzaskowski B; Palczewski K; Filipek S
    Acta Biochim Pol; 2012; 59(4):515-29. PubMed ID: 23251911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor.
    Bhattacharya S; Vaidehi N
    J Am Chem Soc; 2010 Apr; 132(14):5205-14. PubMed ID: 20235532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging structural insights into biased GPCR signaling.
    Shukla AK; Singh G; Ghosh E
    Trends Biochem Sci; 2014 Dec; 39(12):594-602. PubMed ID: 25458114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging opportunities for allosteric modulation of G-protein coupled receptors.
    Wang CI; Lewis RJ
    Biochem Pharmacol; 2013 Jan; 85(2):153-62. PubMed ID: 22975406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands.
    Kooistra AJ; Roumen L; Leurs R; de Esch IJ; de Graaf C
    Methods Enzymol; 2013; 522():279-336. PubMed ID: 23374191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.
    Mohr K; Schmitz J; Schrage R; Tränkle C; Holzgrabe U
    Angew Chem Int Ed Engl; 2013 Jan; 52(2):508-16. PubMed ID: 23225228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of GPCR structures on pharmacology and structure-based drug design.
    Congreve M; Marshall F
    Br J Pharmacol; 2010 Mar; 159(5):986-96. PubMed ID: 19912230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
    Heilker R; Wolff M; Tautermann CS; Bieler M
    Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors.
    Lakkaraju SK; Yu W; Raman EP; Hershfeld AV; Fang L; Deshpande DA; MacKerell AD
    J Chem Inf Model; 2015 Mar; 55(3):700-8. PubMed ID: 25692383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing Class A GPCRs to bitter taste receptors: Structural motifs, ligand interactions and agonist-to-antagonist ratios.
    Di Pizio A; Levit A; Slutzki M; Behrens M; Karaman R; Niv MY
    Methods Cell Biol; 2016; 132():401-27. PubMed ID: 26928553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From three-dimensional GPCR structure to rational ligand discovery.
    Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
    Adv Exp Med Biol; 2014; 796():129-57. PubMed ID: 24158804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development.
    Archbold JK; Flanagan JU; Watkins HA; Gingell JJ; Hay DL
    Trends Pharmacol Sci; 2011 Oct; 32(10):591-600. PubMed ID: 21722971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SnapShot: GPCR-Ligand Interactions.
    Ghosh E; Nidhi K; Shukla AK
    Cell; 2014 Dec; 159(7):1712, 1712.e1. PubMed ID: 25525884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.